Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA</title>
<author><name sortKey="Nilvebrant, Johan" sort="Nilvebrant, Johan" uniqKey="Nilvebrant J" first="Johan" last="Nilvebrant">Johan Nilvebrant</name>
<affiliation><nlm:aff id="A1">School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm, Sweden</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dunlop, D Cameron" sort="Dunlop, D Cameron" uniqKey="Dunlop D" first="D Cameron" last="Dunlop">D Cameron Dunlop</name>
<affiliation><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sircar, Aroop" sort="Sircar, Aroop" uniqKey="Sircar A" first="Aroop" last="Sircar">Aroop Sircar</name>
<affiliation><nlm:aff id="A3">EMD Serono Research Institute; Billlerica, MA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wurch, Thierry" sort="Wurch, Thierry" uniqKey="Wurch T" first="Thierry" last="Wurch">Thierry Wurch</name>
<affiliation><nlm:aff id="A4">Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Falkowska, Emilia" sort="Falkowska, Emilia" uniqKey="Falkowska E" first="Emilia" last="Falkowska">Emilia Falkowska</name>
<affiliation><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M" last="Reichert">Janice M. Reichert</name>
<affiliation><nlm:aff id="A5">Landes Bioscience; Austin, TX USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Helguera, Gustavo" sort="Helguera, Gustavo" uniqKey="Helguera G" first="Gustavo" last="Helguera">Gustavo Helguera</name>
<affiliation><nlm:aff id="A6">Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires, Argentina</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Piccione, Emily C" sort="Piccione, Emily C" uniqKey="Piccione E" first="Emily C" last="Piccione">Emily C. Piccione</name>
<affiliation><nlm:aff id="A7">Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Brack, Simon" sort="Brack, Simon" uniqKey="Brack S" first="Simon" last="Brack">Simon Brack</name>
<affiliation><nlm:aff id="A8">Covagen AG; Zürich Schlieren, Switzerland</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Berger, Sven" sort="Berger, Sven" uniqKey="Berger S" first="Sven" last="Berger">Sven Berger</name>
<affiliation><nlm:aff id="A9">Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois, France</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22453091</idno>
<idno type="pmc">3361653</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361653</idno>
<idno type="RBID">PMC:3361653</idno>
<idno type="doi">10.4161/mabs.4.2.19495</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000336</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000336</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA</title>
<author><name sortKey="Nilvebrant, Johan" sort="Nilvebrant, Johan" uniqKey="Nilvebrant J" first="Johan" last="Nilvebrant">Johan Nilvebrant</name>
<affiliation><nlm:aff id="A1">School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm, Sweden</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dunlop, D Cameron" sort="Dunlop, D Cameron" uniqKey="Dunlop D" first="D Cameron" last="Dunlop">D Cameron Dunlop</name>
<affiliation><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sircar, Aroop" sort="Sircar, Aroop" uniqKey="Sircar A" first="Aroop" last="Sircar">Aroop Sircar</name>
<affiliation><nlm:aff id="A3">EMD Serono Research Institute; Billlerica, MA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wurch, Thierry" sort="Wurch, Thierry" uniqKey="Wurch T" first="Thierry" last="Wurch">Thierry Wurch</name>
<affiliation><nlm:aff id="A4">Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Falkowska, Emilia" sort="Falkowska, Emilia" uniqKey="Falkowska E" first="Emilia" last="Falkowska">Emilia Falkowska</name>
<affiliation><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M" last="Reichert">Janice M. Reichert</name>
<affiliation><nlm:aff id="A5">Landes Bioscience; Austin, TX USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Helguera, Gustavo" sort="Helguera, Gustavo" uniqKey="Helguera G" first="Gustavo" last="Helguera">Gustavo Helguera</name>
<affiliation><nlm:aff id="A6">Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires, Argentina</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Piccione, Emily C" sort="Piccione, Emily C" uniqKey="Piccione E" first="Emily C" last="Piccione">Emily C. Piccione</name>
<affiliation><nlm:aff id="A7">Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Brack, Simon" sort="Brack, Simon" uniqKey="Brack S" first="Simon" last="Brack">Simon Brack</name>
<affiliation><nlm:aff id="A8">Covagen AG; Zürich Schlieren, Switzerland</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Berger, Sven" sort="Berger, Sven" uniqKey="Berger S" first="Sven" last="Berger">Sven Berger</name>
<affiliation><nlm:aff id="A9">Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois, France</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">mAbs</title>
<idno type="ISSN">1942-0862</idno>
<idno type="eISSN">1942-0870</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The 22<sup>nd</sup>
Annual Antibody Engineering and 9<sup>th</sup>
Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5–8, 2011 in San Diego, CA. The meeting drew ∼800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics Conference comprised five sessions: (1) Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.</p>
</div>
</front>
</TEI>
<pmc article-type="brief-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">MAbs</journal-id>
<journal-id journal-id-type="iso-abbrev">MAbs</journal-id>
<journal-id journal-id-type="publisher-id">mAbs</journal-id>
<journal-title-group><journal-title>mAbs</journal-title>
</journal-title-group>
<issn pub-type="ppub">1942-0862</issn>
<issn pub-type="epub">1942-0870</issn>
<publisher><publisher-name>Landes Bioscience</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">22453091</article-id>
<article-id pub-id-type="pmc">3361653</article-id>
<article-id pub-id-type="publisher-id">1942-0862-4-2-3</article-id>
<article-id pub-id-type="doi">10.4161/mabs.4.2.19495</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Meeting Report</subject>
</subj-group>
</article-categories>
<title-group><article-title>IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Nilvebrant</surname>
<given-names>Johan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Dunlop</surname>
<given-names>D Cameron</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sircar</surname>
<given-names>Aroop</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wurch</surname>
<given-names>Thierry</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Falkowska</surname>
<given-names>Emilia</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Reichert</surname>
<given-names>Janice M</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Helguera</surname>
<given-names>Gustavo</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Piccione</surname>
<given-names>Emily C</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Brack</surname>
<given-names>Simon</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Berger</surname>
<given-names>Sven</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm, Sweden</aff>
<aff id="A2"><label>2</label>
The Scripps Research Institute; La Jolla, CA USA</aff>
<aff id="A3"><label>3</label>
EMD Serono Research Institute; Billlerica, MA USA</aff>
<aff id="A4"><label>4</label>
Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine, France</aff>
<aff id="A5"><label>5</label>
Landes Bioscience; Austin, TX USA</aff>
<aff id="A6"><label>6</label>
Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires, Argentina</aff>
<aff id="A7"><label>7</label>
Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA</aff>
<aff id="A8"><label>8</label>
Covagen AG; Zürich Schlieren, Switzerland</aff>
<aff id="A9"><label>9</label>
Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois, France</aff>
<author-notes><corresp>Correspondence to: Janice M. Reichert; Email: <email>janice.reichert@landesbioscience.com</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><season>Mar-Apr</season>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub"><day>1</day>
<month>3</month>
<year>2012</year>
</pub-date>
<volume>4</volume>
<issue>2</issue>
<fpage>153</fpage>
<lpage>181</lpage>
<history><date date-type="received"><day>26</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="accepted"><day>26</day>
<month>1</month>
<year>2012</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2012 Landes Bioscience</copyright-statement>
<copyright-year>2012</copyright-year>
</permissions>
<abstract><p>The 22<sup>nd</sup>
Annual Antibody Engineering and 9<sup>th</sup>
Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5–8, 2011 in San Diego, CA. The meeting drew ∼800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics Conference comprised five sessions: (1) Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.</p>
</abstract>
<kwd-group><title>Key words</title>
<kwd>antibody engineering</kwd>
<kwd>antibody therapeutics</kwd>
<kwd>antibody-drug conjugates</kwd>
<kwd>bispecific antibodies</kwd>
<kwd>computational design</kwd>
<kwd>antibody-antigen structure</kwd>
<kwd>vaccine design</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0003360 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0003360 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |